Biotech has delivered one of its strongest rallies in years, fueled by a resurgence in M&A activity, improving sentiment and continued innovation. But as valuations rise and competition intensifies, investors are becoming increasingly selective. RBC's biotech analysts explore the key drivers behind the rally, the outlook for M&A, the growing role of China and what could determine whether the sector sustains momentum through the second half of the year.

Key Points

• M&A activity, improving regulatory sentiment and strong clinical data have helped drive a significant re-rating across biotech.
• Higher valuations have boosted investor confidence but may leave less room for error in the second half.
• Innovation continues to underpin long-term growth opportunities, although competition is increasing.
• China's growing role in drug development is reshaping competitive dynamics and business development strategies.
• Investors are becoming increasingly selective, with a greater focus on company-specific catalysts and fundamentals.

Chapter Markers

What's driving biotech's rally? [00:52)

• Brian Abrahams explores the key factors behind biotech's resurgence..

Why selectivity matters more now [2:30]

• Rising valuations have strengthened confidence across biotech, but investors may need to become more discerning about where they allocate capital in the second half.

The outlook for biotech M&A [4:02]

• M&A remains a leading catalyst for biotech investors, with deal activity continuing to shape sentiment and sector performance.

What the biotech investor survey revealed [7:11]

• Lisa Walter discusses investor positioning, valuation expectations and why enthusiasm remains constructive despite a more neutral stance following the rally.

Innovation, drug launches and competitive advantage [11:02]

• Leonid Timashev explores how innovation, commercial execution and emerging modalities are shaping competitive advantage in biotech, and why successful launches remain critical to long-term value creation.

China's growing influence in biotech [17:44]

• China's emergence as a leading source of innovation and business development activity is reshaping competitive dynamics across the biotech sector.

What could drive the second half? [20:15]

• RBC analysts discuss the factors most likely to determine whether biotech can sustain its momentum.